Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China NT Pharma Group Co., Ltd. ( (HK:1011) ) has provided an update.
China NT Pharma Group said it expects to book a one-off, non-cash gain of about HK$15.4 million from issuing new shares to settle debt, following discussions with its auditor during the 2025 year-end audit. As a result, the group’s previously flagged loss for the year to 31 December 2025 will narrow, with the revised expected net loss now estimated at between RMB10.9 million and RMB15.9 million.
Other details of the earlier profit warning remain unchanged, and the company has scheduled a board meeting on 31 March 2026 to consider and approve its audited annual results for 2025. The company urged shareholders and potential investors to review the forthcoming annual results announcement carefully and to exercise caution when trading its shares in the meantime.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a pharmaceutical company listed in Hong Kong that operates through a group structure focused on developing and marketing pharmaceutical products in Mainland China and related markets. The group’s activities span the manufacture, distribution and promotion of medicines, positioning it within the broader Chinese healthcare and drug industry.
Average Trading Volume: 288,590
Technical Sentiment Signal: Hold
Current Market Cap: HK$673.8M
Learn more about 1011 stock on TipRanks’ Stock Analysis page.